{"entity":{"id":"fdps","kind":"target","name":"FDPS","aka":["farnesyl diphosphate synthase","Farnesyl pyrophosphate synthase"],"tldr":"FDPS (Farnesyl pyrophosphate synthase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer, Multiple myeloma and Breast cancer.","summary":"Key enzyme in isoprenoid biosynthesis which catalyses the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones. FPP also serves as substrate for protein farnesylation and geranylgeranylation. Catalyses the sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, dimethylallyl pyrophosphate, and then with the resultant geranylpyrophosphate to the ultimate product farnesyl pyrophosphate.\n\nOpen Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.86, genetic association 0.00, clinical 0.99).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:3631","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3631"},{"label":"UniProt P14324","url":"https://www.uniprot.org/uniprotkb/P14324/entry"},{"label":"NCBI Gene 2224","url":"https://www.ncbi.nlm.nih.gov/gene/2224"},{"label":"Ensembl ENSG00000160752","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000160752"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":["prostate","multiple-myeloma","breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.99. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"FDPS","role":["drug-target"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:3631","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3631","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P14324","url":"https://www.uniprot.org/uniprotkb/P14324/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000160752","url":"https://platform.opentargets.org/target/ENSG00000160752/associations","note":"association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: prostate cancer 0.60, plasma cell myeloma 0.60, breast cancer 0.54 (GraphQL API, CC0)"}],"specificity":"broadly-expressed","distribution":"few-types","specificityNote":"Broadly expressed or essential: HPA lists FDPS among essential proteins; a medicine acting on the wild-type protein would expose normal tissue too. HPA FDPS: RNA tissue enhanced (liver 333 nTPM); no normal tissue stained high; highest cancer staining liver cancer (2 of 12 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Prostate cancer, Multiple myeloma, Breast cancer (all types)); Open Targets associates it with 5 specific cancer types at or above 0.5 (plasma cell myeloma, prostate carcinoma, prostate cancer, Paget disease, breast cancer). (Rule 7 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas FDPS tissue","url":"https://www.proteinatlas.org/ENSG00000160752-FDPS/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000160752 associations","url":"https://platform.opentargets.org/target/ENSG00000160752/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:3631","ensembl":"ENSG00000160752","uniprot":"P14324","entrez":"2224","firstDescribed":1989,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Sheares B.T. et al, Biochemistry, 1989, \"Cloning, analysis, and bacterial expression of human farnesyl pyrophosphate synthetase and its regulation in Hep G2 cells\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/2690933/","biology":"Key enzyme in isoprenoid biosynthesis which catalyses the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones. FPP also serves as substrate for protein farnesylation and geranylgeranylation. Catalyses the sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, dimethylallyl pyrophosphate, and then with the resultant geranylpyrophosphate to the ultimate product farnesyl pyrophosphate. Location: Cytoplasm (UniProt). Locus 1q22 (HGNC).","whereFound":["Prostate cancer: Open Targets association 0.60 with prostate cancer (MONDO_0008315)","Multiple myeloma: Open Targets association 0.60 with plasma cell myeloma (MONDO_0009693)","Breast cancer: Open Targets association 0.54 with breast cancer (MONDO_0007254)"],"targetClass":"enzyme","prevalence":[]},"route":"/targets/fdps/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}]}}